Chemgenex hasn't been discussing Berger or Ariad with me. Berger has a very long history of misleading investors. I have been at many conferences and discussed the company, and the managers I speak with say they won't go near him
a couple of years ago I was at a breakout and the fellow I was sitting next to kept asking how long the money will last, because it was running low, and Berger said he wasn't concerned about cash. He did a raise less than a month later.
He didn't technically lie. He wasn't concerned about cash because he knew he was going to raise it, and he wasn't going bankrupt.
And unless you have seen his data, I don't know how you can say that Chemgenex will get its clock cleaned.
Have you seen the data?
Chemgenex was able to do the open label study in the t315i mutation because there was no drug approved that treated it. Once Omacetaxine is approved, he would have to do a study versus, or with Omacetaxine, he won't be able to run an open label study so it won't be that easy to recruit.
If Omacetaxine is approved early next year Ariad would probably have to run a trial of his tki with omacetaxine vs. his tki alone imho
That is okay with me
That is me saying that, not chemgenex.
